All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Initiation of the first-in-human trial of FHD-286, a first-in-class dual inhibitor, to treat R/R AML

May 20, 2021

Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes have very limited curative treatment options; therefore, the development of novel therapeutics remains of high importance for the future. On May 17, 2021, an announcement was made about the first patient dosed in a first-in-human and first-in-class clinical study of FHD-286 for the treatment of relapsed/refractory AML. The dose-escalation trial is evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of FHD-286 administered orally as a monotherapy.

FHD-286 is the first clinical candidate of a new class of inhibitors of the BAF chromatin remodeling complex ATPases BRG1 and BRM proteins, directly targeting the genetically determined dependencies of hematologic malignancies within the chromatin regulatory system. FHD-286 is characterized as a highly potent, allosteric, and selective small-molecule enzymatic inhibitor. In preclinical studies, FHD-286 has shown antitumor activity across a broad range of cancers.

  1. Foghorn Therapeutics announces dosing of first patient in first-in-human clinical program of FHD-286. Published May 17, 2021. Accessed May 19, 2021.